A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption

Clinical Immunology

Volumn 142, Issue 3, 2012, Pages 252-268

  Allard, Sabine D ^a,b   De Keersmaecker, Brenda ^b   de Goede, Anna L ^c   Verschuren, Esther J ^c   Koetsveld, Jeanette ^c   Reedijk, Mariska L ^c   Wylock, Carolien ^a   De Bel, Annelies V ^a   Vandeloo, Judith ^d   Pistoor, Frank ^e   Heirman, Carlo ^b   Beyer, Walter E P ^c   Eilers, Paul H C ^c   Corthals, Jurgen ^b   Padmos, Iman ^c   Thielemans, Kris ^b   Osterhaus, Albert D M E ^c   Lacor, Patrick ^a   der Ende, Marchina E van ^c   Aerts, Joeri L ^b   van Baalen, Carel A ^c   Gruters, Rob A ^c   more..

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d Rode Kruis Vlaanderen   (Belgium)

^e ViroClinics Biosciences   (Netherlands)

Author keywords

Dendritic cells; Early expressed proteins; HIV 1; T cell responses; Therapeutic vaccination

Indexed keywords

ANTIGEN; DENDRITIC CELL VACCINE; MESSENGER RNA; NEF PROTEIN; REV PROTEIN; TRANSACTIVATOR PROTEIN;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROPORATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNOTHERAPY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION; VIRUS IMMUNITY; VIRUS LOAD;

ADULT; AGED; AIDS VACCINES; CELLS, CULTURED; DENDRITIC CELLS; GENE PRODUCTS, REV; GENE PRODUCTS, TAT; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION; MALE; MIDDLE AGED; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84857374529     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2011.10.010     Document Type: Article

References (89)

1. UNAIDS report on the global AIDS epidemic last date of access: August 2011. http://www.unaids.org/globalreport/Global_report.htm.
2. Palella F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., Aschman D.J., Holmberg S.D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 1998, 338:853-860.
3. Richman D.D., Margolis D.M., Delaney M., Greene W.C., Hazuda D., Pomerantz R.J. The challenge of finding a cure for HIV infection. Science 2009, 323:1304-1307.
4. Autran B., Debré P., Walker B., Katlama C. Therapeutic vaccines against HIV need international partnerships. Nat. Rev. Immunol. 2003, 3:503-508.
5. Finzi D., Blankson J., Siliciano J., Margolick J., Chadwick K., Pierson T., Smith K., Lisziewicz J., Lori F., Flexner C., Quinn T., Chaisson R., Rosenberg E., Walker B., Gange S., Gallant J., Siliciano R. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 1999, 5:512-517.
6. Pitcher C.J., Quittner C., Peterson D.M., Connors M., Koup R.A., Maino V.C., Picker L.J. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat. Med. 1999, 5:518-525.
7. Mollet L., Li T.S., Samri A., Tournay C., Tubiana R., Calvez V., Debré P., Katlama C., Autran B. Dynamics of HIV-specific CD8+ T lymphocytes with changes in viral load. The RESTIM and COMET Study Groups. J. Immunol. 2000, 165:1692-1704.
8. Autran B., Costagliola D., Murphy R., Katlama C. Evaluating therapeutic vaccines in patients infected with HIV. Expert Rev. Vaccines 2004, 3:S169-S177.
9. McMichael A.J. HIV vaccines. Annu. Rev. Immunol. 2006, 24:227-255.
10. Appay V. 25years of HIV research! and what about a vaccine?. Eur. J. Immunol. 2009, 39:1999-2003.
11. Yang O.O. Will we be able to 'spot' an effective HIV-1 vaccine?. Trends Immunol. 2003, 24:67-72.
12. Pantaleo G., Koup R. Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat. Med. 2004, 10:806-810.
13. Gotch F., Gallimore A., McMichael A. Cytotoxic T cells-protection from disease progression-protection from infection. Immunol. Lett. 1996, 51:125-128.
14. Heeney J.L. The critical role of CD4(+) T-cell help in immunity to HIV. Vaccine 2002, 20:1961-1963.
15. Bangham C.R. CTL quality and the control of human retroviral infections. Eur. J. Immunol. 2009, 39:1700-1712.
16. Palucka K., Banchereau J., Mellman I. Designing vaccines based on biology of human dendritic cell subsets. Immunity 2010, 33:464-478.
17. Routy J.P., Boulassel M.R., Yassine-Diab B., Nicolette C., Healey D., Jain R., Landry C., Yegorov O., Tcherepanova I., Monesmith T., Finke L., Sékaly R.P. Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy. Clin. Immunol. 2010, 134:140-147.
18. Kloverpris H., Karlsson I., Bonde J., Thorn M., Vinner L., Pedersen A.E., Hentze J.L., Andresen B.S., Svane I.M., Gerstoft J., Kronborg G., Fomsgaard A. Induction of novel CD8+ T-cell responses during chronic untreated HIV-1 infection by immunization with subdominant cytotoxic T-lymphocyte epitopes. AIDS 2009, 23:1329-1340.
19. Gandhi R.T., O'Neill D., Bosch R.J., Chan E.S., Bucy R.P., Shopis J., Baglyos L., Adams E., Fox L., Purdue L., Marshak A., Flynn T., Masih R., Schock B., Mildvan D., Schlesinger S.J., Marovich M.A., Bhardwaj N., Jacobson J.M. A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy. Vaccine 2009, 27:6088-6094. A.C.T.G.A. team.
20. Connolly N., Whiteside T., Wilson C., Kondragunta V., Rinaldo C., Riddler S. Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals. Clin. Vaccine Immunol. 2008, 15:284-292.
21. García F., Lejeune M., Climent N., Gil C., Alcamí J., Morente V., Alós L., Ruiz A., Setoain J., Fumero E., Castro P., López A., Cruceta A., Piera C., Florence E., Pereira A., Libois A., González N., Guilá M., Caballero M., Lomeña F., Joseph J., Miró J., Pumarola T., Plana M., Gatell J., Gallart T. Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. J. Infect. Dis. 2005, 191:1680-1685.
22. Lu W., Arraes L., Ferreira W., Andrieu J. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat. Med. 2004, 10:1359-1365.
23. Ide F., Nakamura T., Tomizawa M., Kawana-Tachikawa A., Odawara T., Hosoya N., Iwamoto A. Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a phase 1 trial. J. Med. Virol. 2006, 78:711-718.
24. Kundu S.K., Engleman E., Benike C., Shapero M.H., Dupuis M., van Schooten W.C., Eibl M., Merigan T.C. A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients. AIDS Res. Hum. Retroviruses 1998, 14:551-560.
25. Rinaldo C.R. Dendritic cell-based human immunodeficiency virus vaccine. J. Intern. Med. 2009, 265:138-158.
26. Van Gulck E., Van Tendeloo V.F., Berneman Z.N., Vanham G. Role of dendritic cells in HIV-immunotherapy. Curr. HIV Res. 2010, 8:310-322.
27. García F., Climent N., Assoumou L., Gil C., González N., Alcamí J., León A., Romeu J., Dalmau J., Martínez-Picado J., Lifson J., Autran B., Costagliola D., Clotet B., Gatell J.M., Plana M., Gallart T. A therapeutic dendritic cell-based vaccine for HIV-1 infection. J. Infect. Dis. 2011, 203:473-478. D.M.-A.V.R.O.S. Group.
28. García F., Routy J.P. Challenges in dendritic cells-based therapeutic vaccination in HIV-1 infection Workshop in dendritic cell-based vaccine clinical trials in HIV-1. Vaccine 2011, 29:6454-6463.
29. Haas J., Park E.C., Seed B. Codon usage limitation in the expression of HIV-1 envelope glycoprotein. Curr. Biol. 1996, 6:315-324.
30. Peng B., Robert-Guroff M. Deletion of N-terminal myristoylation site of HIV Nef abrogates both MHC-1 and CD4 down-regulation. Immunol. Lett. 2001, 78:195-200.
31. De Keersmaecker B., Heirman C., Allard S., Bonehill A., Corthals J., Thielemans K., Aerts J. Lumenal part of the DC-LAMP protein is not required for induction of antigen-specific T cell responses by means of antigen-DC-LAMP messenger RNA-electroporated dendritic cells. Hum. Gene Ther. 2010, 21:479-485.
32. Mitchell D.A., Nair S.K. RNA transfected dendritic cells as cancer vaccines. Curr. Opin. Mol. Ther. 2000, 2:176-181.
33. Mitchell D.A., Nair S.K. RNA-transfected dendritic cells in cancer immunotherapy. J. Clin. Invest. 2000, 106:1065-1069.
34. *5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte [corrected] recognition. J. Virol. 2009, 83:2743-2755.
35. *57 and chimpanzee MHC class I molecules target analogous conserved areas of HIV-1/SIVcpz. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:15175-15180.
36. Julg B., Williams K.L., Reddy S., Bishop K., Qi Y., Carrington M., Goulder P.J., Ndung'u T., Walker B.D. Enhanced anti-HIV functional activity associated with Gag-specific CD8 T-cell responses. J. Virol. 2010, 84:5540-5549.
37. Rolland M., Heckerman D., Deng W., Rousseau C.M., Coovadia H., Bishop K., Goulder P.J., Walker B.D., Brander C., Mullins J.I. Broad and Gag-biased HIV-1 epitope repertoires are associated with lower viral loads. PLoS One 2008, 3:e1424.
38. Pereyra F., Addo M.M., Kaufmann D.E., Liu Y., Miura T., Rathod A., Baker B., Trocha A., Rosenberg R., Mackey E., Ueda P., Lu Z., Cohen D., Wrin T., Petropoulos C.J., Rosenberg E.S., Walker B.D. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J. Infect. Dis. 2008, 197:563-571.
39. Kosmrlj A., Read E.L., Qi Y., Allen T.M., Altfeld M., Deeks S.G., Pereyra F., Carrington M., Walker B.D., Chakraborty A.K. Effects of thymic selection of the T-cell repertoire on HLA class I-associated control of HIV infection. Nature 2010, 465:350-354.
40. Osterhaus A.D., van Baalen C.A., Gruters R.A., Schutten M., Siebelink C.H., Hulskotte E.G., Tijhaar E.J., Randall R.E., van Amerongen G., Fleuchaus A., Erfle V., Sutter G. Vaccination with Rev and Tat against AIDS. Vaccine 1999, 17:2713-2714.
41. Gruters R., van Baalen C., Osterhaus A. The advantage of early recognition of HIV-infected cells by cytotoxic T-lymphocytes. Vaccine 2002, 20:2011-2015.
42. van Baalen C.A., Stittelaar K.J., Osterhaus A.D., Guillon C., Gruters R.A. The choice of antigen for therapeutic immunization against AIDS. Trends Immunol. 2002, 23:478-479.
43. Stittelaar K.J., Gruters R.A., Schutten M., van Baalen C.A., van Amerongen G., Cranage M., Liljeström P., Sutter G., Osterhaus A.D. Comparison of the efficacy of early versus late viral proteins in vaccination against SIV. Vaccine 2002, 20:2921-2927.
44. Pauza C.D., Trivedi P., Wallace M., Ruckwardt T.J., Le Buanec H., Lu W., Bizzini B., Burny A., Zagury D., Gallo R.C. Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:3515-3519.
45. Hansen S.G., Vieville C., Whizin N., Coyne-Johnson L., Siess D.C., Drummond D.D., Legasse A.W., Axthelm M.K., Oswald K., Trubey C.M., Piatak M., Lifson J.D., Nelson J.A., Jarvis M.A., Picker L.J. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat. Med. 2009, 15:293-299.
46. Cafaro A., Caputo A., Fracasso C., Maggiorella M.T., Goletti D., Baroncelli S., Pace M., Sernicola L., Koanga-Mogtomo M.L., Betti M., Borsetti A., Belli R., Akerblom L., Corrias F., Buttò S., Heeney J., Verani P., Titti F., Ensoli B. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nat. Med. 1999, 5:643-650.
47. Hel Z., Johnson J., Tryniszewska E., Tsai W., Harrod R., Fullen J., Tartaglia J., Franchini G. A novel chimeric Rev, Tat, and Nef (Retanef) antigen as a component of an SIV/HIV vaccine. Vaccine 2002, 20:3171-3186.
48. Wilson N.A., Reed J., Napoe G.S., Piaskowski S., Szymanski A., Furlott J., Gonzalez E.J., Yant L.J., Maness N.J., May G.E., Soma T., Reynolds M.R., Rakasz E., Rudersdorf R., McDermott A.B., O'Connor D.H., Friedrich T.C., Allison D.B., Patki A., Picker L.J., Burton D.R., Lin J., Huang L., Patel D., Heindecker G., Fan J., Citron M., Horton M., Wang F., Liang X., Shiver J.W., Casimiro D.R., Watkins D.I. Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J. Virol. 2006, 80:5875-5885.
49. Allard S., Pletinckx K., Breckpot K., Heirman C., Bonehill A., Michiels A., van Baalen C., Gruters R., Osterhaus A., Lacor P., Thielemans K., Aerts J. Functional T-cell responses generated by dendritic cells expressing the early HIV-1 proteins Tat, Rev and Nef. Vaccine 2008, 26:3735-3741.
50. Voeten J., Bestebroer T., Nieuwkoop N., Fouchier R., Osterhaus A., Rimmelzwaan G. Antigenic drift in the influenza A virus (H3N2) nucleoprotein and escape from recognition by cytotoxic T lymphocytes. J. Virol. 2000, 74:6800-6807.
51. Tuyaerts S., Noppe S., Corthals J., Breckpot K., Heirman C., De Greef C., Van Riet I., Thielemans K. Generation of large numbers of dendritic cells in a closed system using Cell Factories. J. Immunol. Methods 2002, 264:135-151.
52. Achenbach C.J., Till M., Palella F.J., Knoll M.D., Terp S.M., Kalnins A.U., Murphy R.L. Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA. HIV Med. 2005, 6:7-12.
53. Boschi A., Tinelli C., Ortolani P., Moscatelli G., Morigi G., Arlotti M. CD4+ cell-count-guided treatment interruptions in chronic HIV-infected patients with good response to highly active antiretroviral therapy. AIDS 2004, 18:2381-2389.
54. Davey R.T., Bhat N., Yoder C., Chun T.W., Metcalf J.A., Dewar R., Natarajan V., Lempicki R.A., Adelsberger J.W., Miller K.D., Kovacs J.A., Polis M.A., Walker R.E., Falloon J., Masur H., Gee D., Baseler M., Dimitrov D.S., Fauci A.S., Lane H.C. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:15109-15114.
55. Jacobs B., Neil N., Aboulafia D.M. Retrospective analysis of suspending HAART in selected patients with controlled HIV replication. AIDS Patient Care STDS 2005, 19:429-438.
56. Krolewiecki A.J., Zala C., Vanzulli C., Pérez H., Iannella M.e.C., Bouzas M.B., Gun A., Valiente J., Cassetti I., Cahn P. Safe treatment interruptions in patients with nadir CD4 counts of more than 350 cells/microL: a randomized trial. J. Acquir. Immune Defic. Syndr. 2006, 41:425-429.
57. Maggiolo F., Ripamonti D., Gregis G., Quinzan G., Callegaro A., Suter F. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial. AIDS 2004, 18:439-446.
58. Mata R.C., Viciana P., de Alarcón A., López-Cortés L.F., Gómez-Vera J., Trastoy M., Cisneros J.M. Discontinuation of antiretroviral therapy in patients with chronic HIV infection: clinical, virologic, and immunologic consequences. AIDS Patient Care STDS 2005, 19:550-562.
59. Moltó J., Ruiz L., Romeu J., Martínez-Picado J., Negredo E., Tural C., Sirera G., Clotet B. Influence of prior structured treatment interruptions on the length of time without antiretroviral treatment in chronically HIV-infected subjects. AIDS Res. Hum. Retroviruses 2004, 20:1283-1288.
60. Papasavvas E., Kostman J.R., Mounzer K., Grant R.M., Gross R., Gallo C., Azzoni L., Foulkes A., Thiel B., Pistilli M., Mackiewicz A., Shull J., Montaner L.J. Randomized, controlled trial of therapy interruption in chronic HIV-1 infection. PLoS Med. 2004, 1:e64.
61. Pellegrin I., Thiébaut R., Blanco P., Viallard J.F., Schrive M.H., Merel P., Chêne G., Fleury H., Moreau J.F., Pellegrin J.L. Can highly active antiretroviral therapy be interrupted in patients with sustained moderate HIV RNA and >400 CD4+ cells/microl? Impact on immunovirological parameters. J. Med. Virol. 2005, 77:164-172.
62. 3: 48-week Treatment Interruption in Early Starters Netherlands Study (TRIESTAN). J. Acquir. Immune Defic. Syndr. 2007, 44:395-400.
63. Ruiz L., Paredes R., Gómez G., Romeu J., Domingo P., Pérez-Alvarez N., Tambussi G., Llibre J.M., Martínez-Picado J., Vidal F., Fumaz C.R., Clotet B. Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients. AIDS 2007, 21:169-178. T.S. Group.
64. Skiest D.J., Su Z., Havlir D.V., Robertson K.R., Coombs R.W., Cain P., Peterson T., Krambrink A., Jahed N., McMahon D., Margolis D.M. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170. J. Infect. Dis. 2007, 195:1426-1436. A.C.T.G.S. Team.
65. Vallejo A., Valladares A., De Felipe B., Vivancos J., Gutierrez S., Soriano-Sarabia N., Ruiz-Mateos E., Lissen E., Leal M. High thymic volume is associated with viral replication and immunologic impairment only early after HAART interruption in chronic HIV infection. Viral Immunol. 2005, 18:740-746.
66. Wit F.W., Blanckenberg D.H., Brinkman K., Prins J.M., van der Ende M.E., Schneider M.M., Mulder J.W., de Wolf F., Lange J.M. Safety of long-term interruption of successful antiretroviral therapy: the ATHENA cohort study. AIDS 2005, 19:345-348. A.S. Group.
67. Moodie Z., Price L., Gouttefangeas C., Mander A., Janetzki S., Löwer M., Welters M.J., Ottensmeier C., van der Burg S.H., Britten C.M. Response definition criteria for ELISPOT assays revisited. Cancer Immunol. Immunother. 2010, 59:1489-1501.
68. Moodie Z., Price L., Janetzki S., Britten C.M. Response determination criteria for ELISPOT: toward a standard that can be applied across laboratories. Methods Mol. Biol. 2012, 792:185-196.
69. Routy J.P., Angel J., Vezina S., Tremblay C., Loutfy M., Gill J., Baril J., Smail F., Boulassel M.R., Tcherepanova I.Y., DeBenedette M., Jain R.G., Nicolette C.A. Final analysis of a phase 2 study of an autologous dendritic cell immunotherapy (AGS-004) showed positive outcomes in primary endpoint of viral load control, and favorable safety and immunogenicity profile, in subjects undergoing structural treatment interruption of ART. 18th CROI, Boston 2011, AGS 004-001 study group, poster #H-114.
70. Angel J.B., Routy J.P., Tremblay C., Ayers D., Woods R., Singer J., Bernard N., Kovacs C., Smaill F., Gurunathan S., Sekaly R.P. A randomized controlled trial of HIV therapeutic vaccination using ALVAC with or without Remune. AIDS 2011, 25:731-739.
71. Dorrell L., Yang H., Iversen A., Conlon C., Suttill A., Lancaster M., Dong T., Cebere I., Edwards A., Rowland-Jones S., Hanke T., McMichael A. Therapeutic immunization of highly active antiretroviral therapy-treated HIV-1-infected patients: safety and immunogenicity of an HIV-1 gag/poly-epitope DNA vaccine. AIDS 2005, 19:1321-1323.
72. Tubiana R., Carcelain G., Vray M., Gourlain K., Dalban C., Chermak A., Rabian C., Vittecoq D., Simon A., Bouvet E., El Habib R., Costagliola D., Calvez V., Autran B., Katlama C. Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: the Vacciter Study (ANRS 094). Vaccine 2005, 23:4292-4301.
73. Falk K., Rötzschke O., Stevanović S., Jung G., Rammensee H. Pool sequencing of natural HLA-DR, DQ, and DP ligands reveals detailed peptide motifs, constraints of processing, and general rules. Immunogenetics 1994, 39:230-242.
74. Duttagupta P.A., Boesteanu A.C., Katsikis P.D. Costimulation signals for memory CD8+ T cells during viral infections. Crit. Rev. Immunol. 2009, 29:469-486.
75. Migueles S., Laborico A., Shupert W., Sabbaghian M., Rabin R., Hallahan C., Van Baarle D., Kostense S., Miedema F., McLaughlin M., Ehler L., Metcalf J., Liu S., Connors M. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat. Immunol. 2002, 3:1061-1068.
76. Younes S., Yassine-Diab B., Dumont A., Boulassel M., Grossman Z., Routy J., Sekaly R. HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. J. Exp. Med. 2003, 198:1909-1922.
77. Kiepiela P., Ngumbela K., Thobakgale C., Ramduth D., Honeyborne I., Moodley E., Reddy S., de Pierres C., Mncube Z., Mkhwanazi N., Bishop K., van der Stok M., Nair K., Khan N., Crawford H., Payne R., Leslie A., Prado J., Prendergast A., Frater J., McCarthy N., Brander C., Learn G., Nickle D., Rousseau C., Coovadia H., Mullins J., Heckerman D., Walker B., Goulder P. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat. Med. 2007, 13:46-53.
78. Appay V., Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J. Pathol. 2008, 214:231-241.
79. De Keersmaecker B., Heirman C., Corthals J., Empsen C., van Grunsven L.A., Allard S.D., Pen J., Lacor P., Thielemans K., Aerts J.L. The combination of 4-1BBL and CD40L strongly enhances the capacity of dendritic cells to stimulate HIV-specific T cell responses. J. Leukoc. Biol. 2011, 89:989-999.
80. Hogg R.S., Yip B., Chan K.J., Wood E., Craib K.J., O'Shaughnessy M.V., Montaner J.S. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001, 286:2568-2577.
81. Lange C.G., Lederman M.M., Medvik K., Asaad R., Wild M., Kalayjian R., Valdez H. Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection. AIDS 2003, 17:2015-2023.
82. Pialoux G., Quercia R.P., Gahery H., Daniel N., Slama L., Girard P.M., Bonnard P., Rozenbaum W., Schneider V., Salmon D., Guillet J.G. Immunological responses and long-term treatment interruption after human immunodeficiency virus type 1 (HIV-1) lipopeptide immunization of HIV-1-infected patients: the LIPTHERA study. Clin. Vaccine Immunol. 2008, 15:562-568.
83. 3. J. Infect. Dis. 2005, 192:1787-1793.
84. Betts M.R., Ambrozak D.R., Douek D.C., Bonhoeffer S., Brenchley J.M., Casazza J.P., Koup R.A., Picker L.J. Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection. J. Virol. 2001, 75:11983-11991.
85. Addo M., Yu X., Rathod A., Cohen D., Eldridge R., Strick D., Johnston M., Corcoran C., Wurcel A., Fitzpatrick C., Feeney M., Rodriguez W., Basgoz N., Draenert R., Stone D., Brander C., Goulder P., Rosenberg E., Altfeld M., Walker B. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J. Virol. 2003, 77:2081-2092.
86. Sacha J.B., Chung C., Rakasz E.G., Spencer S.P., Jonas A.K., Bean A.T., Lee W., Burwitz B.J., Stephany J.J., Loffredo J.T., Allison D.B., Adnan S., Hoji A., Wilson N.A., Friedrich T.C., Lifson J.D., Yang O.O., Watkins D.I. Gag-specific CD8+ T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression. J. Immunol. 2007, 178:2746-2754.
87. Sacha J.B., Reynolds M.R., Buechler M.B., Chung C., Jonas A.K., Wallace L.T., Weiler A.M., Lee W., Piaskowski S.M., Soma T., Friedrich T.C., Wilson N.A., Watkins D.I. Differential antigen presentation kinetics of CD8+ T-cell epitopes derived from the same viral protein. J. Virol. 2008, 82:9293-9298.
88. Sacha J.B., Giraldo-Vela J.P., Buechler M.B., Martins M.A., Maness N.J., Chung C., Wallace L.T., León E.J., Friedrich T.C., Wilson N.A., Hiraoka A., Watkins D.I. Gag- and Nef-specific CD4+ T cells recognize and inhibit SIV replication in infected macrophages early after infection. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:9791-9796.
89. Van Gulck E., Van Tendeloo V.F., Vlieghe E., Vekemans M., Van de Velde A., Smits E., Anguille S., Cools N., Stein B., Nijs G., Goossens H., Mertens L., De Haes W., Merlijn C., Atkinson D., Wong J., Florence E., Vanham G., Berneman Z. Stimulation of antiviral cellular immune responses by therapeutic vaccination of HIV-1-infected patients with dendritic cells transfected with gag, tat, rev and nef mRNA, Conference abstract. Retrovirology 2011, 8(Suppl.2). p76.